NCT06181084View on ClinicalTrials.gov

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Healthy
Interventions
DRUG

LY3410738

Administered orally.

DRUG

Esomeprazole

Administered orally.

Trial Locations (1)

32117

Labcorp Clinical Research, Daytona Beach

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY